Research programme: anti-CD32B monoclonal antibodies - MacroGenics

Drug Profile

Research programme: anti-CD32B monoclonal antibodies - MacroGenics

Alternative Names: CD32 MAB; CD32B monoclonal antibody; MGA 321

Latest Information Update: 16 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MacroGenics
  • Class Monoclonal antibodies
  • Mechanism of Action Fc gamma receptor IIB antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Non-Hodgkin's lymphoma

Most Recent Events

  • 16 Feb 2016 Discontinued - Preclinical for Cancer in USA (Injection)
  • 16 Feb 2016 Discontinued - Preclinical for Non-Hodgkin's lymphoma in USA (Parenteral)
  • 09 Oct 2006 Preclinical trials in Non-Hodgkin's lymphoma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top